Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AH009
- Development stage
- Preclinical
- Lead developer
- Apricity Health
01
Overview
AH009 is an early-stage preclinical precision oncology candidate being developed by Apricity Health. It is part of a pipeline of therapies designed to address the needs of cancer patients who do not respond to existing standard-of-care treatments. The development of AH009 is guided by Apricity Health's human-insight-based approach, which utilizes real-world data to identify targets driving treatment resistance and blood-based biomarkers for patient identification. As of the current pipeline status, AH009 is in the early preclinical phase, focusing on target validation and the establishment of composition of matter.
Beyond the preview
Go deeper on AH009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AH009.